Antimicrobial therapy of acute diarrhoea: a clinical review

References

• Papers of special note have been highlighted as:
   Google Scholar
• • of interest
   Google Scholar
• •• of considerable interest
   Google Scholar
• Lübbert C, Weis S. [Drug therapy of infectious diarrhea. Part 1: infectious diarrhea]. Internist. 2013;54:1383–1392.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Diarrhoeal disease. Fact Sheet No. 330, 2013 Apr [cited 2015 Sep 30]. Available from: http://www.who.int/mediacentre/factsheets/fs330/en/.
   Google Scholar
• Wilking H, Spitznagel H, Werber D, et al. Acute gastrointestinal illness in adults in Germany: a population-based telephone survey. Epidemiol Infect. 2013;141:2365–2375.
   PubMed Web of Science ®Google Scholar
• Roy SL, Scallan E, Beach MJ. The rate of acute gastrointestinal illness in developed countries. J Water Health. 2006;4(Suppl. 2):31–69.
   PubMedGoogle Scholar
• DuPont HL. Acute infectious diarrhea in immunocompetent adults. N Engl J Med. 2014;370:1532–1540.
   PubMed Web of Science ®Google Scholar

• Comprehensive review on all aspects of acute infectious diarrhoea in immunocompetent adults focusing on North American experience.

• Zollner-Schwetz I, Krause R. Therapy of acute gastroenteritis: role of antibiotics. Clin Microbiol Infect. 2015;21:744–749.
   PubMed Web of Science ®Google Scholar
• Wong HB. Rice gruel in management of infantile diarrhoea. Singapore Med J. 1985;26:329–336.
   PubMedGoogle Scholar
• World Health Organization (WHO). Oral rehydration salts: production of the new ORS. [cited 2015 Sep 30]. Available from: http://apps.who.int/iris/bitstream/10665/69227/1/WHO_FCH_CAH_06.1.pdf
   Google Scholar
• Wong CS, Jelacic S, Habeeb RI, et al. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med. 2000;342:1930–1936.
   PubMed Web of Science ®Google Scholar
• Wistrom J, Jertborn M, Ekwall E, et al. Empiric treatment of acute diarrheal disease with norfloxacin. A randomized, placebo-controlled study. Swedish Study Group. Ann Intern Med. 1992;117:202–208.
   PubMed Web of Science ®Google Scholar
• Onwuezobe IA, Oshun PO, Odigwe CC. Antimicrobials for treating symptomatic non-typhoidal Salmonella infection. Cochrane Database Syst Rev. 2012;11:CD001167.
   PubMedGoogle Scholar

•• Current Cochrane analysis on the antimicrobial treatment of symptomatic non-typhoidal Salmonella infections.

• Lübbert C, John E, von Müller L. Clostridium difficile-infection (CDI): guideline-based diagnosis and treatment. Dtsch Arztebl Int. 2014;111:723–3.
   PubMed Web of Science ®Google Scholar

• Comprehensive review on all aspects of the guideline-based treatment of CDI focusing on Europe.

• Jernberg C, Löfmark S, Edlund C, et al. Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiology. 2010;156:3216–3223.
   PubMed Web of Science ®Google Scholar
• Parry CM, Basnyat B, Crump JA. The management of antimicrobial-resistant enteric fever. Expert Rev Anti Infect Ther. 2013;11:1259–1261.
   PubMed Web of Science ®Google Scholar
• Klontz KC, Singh N. Treatment of drug-resistant Shigella infections. Expert Rev Anti Infect Ther. 2015;13:69–80.
   PubMed Web of Science ®Google Scholar
• Lübbert C, Straube L, Stein C, et al. Colonization with extended-spectrum beta-lactamase (ESBL)-producing and carbapenemase-producing Enterobacteriaceae in international travelers returning to Germany. Int J Med Microbiol. 2015;305:148–156.
   PubMed Web of Science ®Google Scholar
• Tribble DR, Sanders JW, Pang LW, et al. Traveller’s diarrhea in Thailand: randomized double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen. Clin Infect Dis. 2007;44:338–346.
   PubMed Web of Science ®Google Scholar
• Hong KS, Kim JS. Rifaximin for the treatment of acute infectious diarrhea. Therap Adv Gastroenterol. 2011;4:227–235.
   PubMedGoogle Scholar

• Comprehensive review on the treatment of acute infectious diarrhea and the chemoprophylaxis of TD with rifaximin.

• Sullivan A, Edlund C, Nord CE. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis. 2001;1:101–114.
   PubMedGoogle Scholar
• Bartels C, Beaute J, Fraser G, et al. Annual epidemiological report 2014: food- and waterborne diseases and zoonoses. Stockholm: ECDC; 2014 [cited 2015 Oct 10]. Available from http://ecdc.europa.eu/en/publications/_layouts/forms/Publication_DispForm.aspx?List=4f55ad51-4aed-4d32-b960-af70113dbb90&ID=1210.
   Google Scholar
• Spina A, Kerr KG, Cormican M, et al. Spectrum of enteropathogens detected by FilmArray GI Panel in a multi-centre study of community-acquired gastroenteritis. Clin Microbiol Infect. 2015;21:719–728.
   PubMed Web of Science ®Google Scholar
• Nataro JP, Mai V, Johnson J, et al. Diarrheagenic Escherichia coli infection in Baltimore, Maryland, and New Haven, Connecticut. Clin Infect Dis. 2006;43:402–407.
   PubMed Web of Science ®Google Scholar
• Huhulescu S, Kiss R, Brettlecker M, et al. Etiology of acute gastroenteritis in three sentinel general practices, Austria 2007. Infection. 2009;37:103–108.
   PubMed Web of Science ®Google Scholar
• Bauer MP, Kuijper EJ. Potential sources of Clostridium difficile in human infection. Infect Dis Clin North Am. 2015;29:29–35.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control (ECDC). Prevention of norovirus infection in schools and childcare facilities. Stockholm: ECDC; 2013 [cited 2015 Oct 10]. Available from http://ecdc.europa.eu/en/publications/Publications/norovirus-prevention-infection-schools-childcare-facilities.pdf
   Google Scholar
• Krones E, Högenauer C. Diarrhea in the immunocompromised patient. Gastroenterol Clin North Am. 2012;41:677–701.
   PubMed Web of Science ®Google Scholar
• Steffen R, Hill DR, DuPont HL. Traveler’s diarrhea: a clinical review. JAMA. 2015;313:71–80.
   PubMed Web of Science ®Google Scholar

•• Crisp and comprehensive review on all aspects of TD.

• Shlim DR. Looking for evidence that personal hygiene precautions prevent traveler’s diarrhea. Clin Infect Dis. 2005;41(Suppl. 8):S531–535.
   PubMed Web of Science ®Google Scholar
• Baird-Parker AC. Foodborne salmonellosis. Lancet. 1990;336:1231–1235.
   PubMed Web of Science ®Google Scholar
• European Food Safety Authority, European Centre for Disease Prevention and Control. The European Union Summary Report on antimicrobial resistance in zoonotic and indicator bacteria from humans, animals and food in 2011. EFSA J. 2013;11:3196–3555.
   Google Scholar
• Day MR, Meunier D, Doumith M, et al. Carbapenemase-producing Salmonella enterica isolates in the UK. J Antimicrob Chemother. 2015;70:2165–2167.
   PubMed Web of Science ®Google Scholar
• Christopher PR, David KV, John SM, et al. Antibiotic therapy for Shigella dysentery. Cochrane Database Syst Rev. 2010;8:CD006784.
   PubMed Web of Science ®Google Scholar

• Cochrane analysis on the antimicrobial treatment of Shigella infections.

• Kosek M, Yori PP, Olortegui MP. Shigellosis update: advancing antibiotic resistance, investment empowered vaccine development, and green bananas. Curr Opin Infect Dis. 2010;23:475–480.
   PubMed Web of Science ®Google Scholar
• Taneja N. Changing epidemiology of shigellosis and emergence of ciprofloxacin-resistant Shigellae in India. J Clin Microbiol. 2007;45:678–679.
   PubMed Web of Science ®Google Scholar
• Blaser MJ, Reller LB. Campylobacter enteritis. N Engl J Med. 1981;305:1444–1452.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick BD, Tribble DR. Update on human Campylobacter jejuni infections. Curr Opin Gastroenterol. 2010;27:1–7.
   Web of Science ®Google Scholar
• Lehtopolku M, Kotilainen P, Haanpera-Heikkinen M, et al. Ribosomal mutations as the main cause of macrolide resistance in Campylobacter jejuni and Campylobacter coli. Antimicrob Agents Chemother. 2011;55:5939–5941.
   PubMed Web of Science ®Google Scholar
• Buchholz U, Bernard H, Werber D, et al. German outbreak of Escherichia coli O104:H4 associated with sprouts. N Engl J Med. 2011;365:1763–1770.
   PubMed Web of Science ®Google Scholar

•• Comprehensive portrayal of the greatest outbreak yet of Shiga toxin-producing enteroaggregative Escherichia coli (STEC O104:H4) in the world in Germany in 2011.

• Nitschke M, Sayk F, Hartel C, et al. Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative Escherichia coli O104:H4. JAMA. 2012;307:1046–1052.
   PubMed Web of Science ®Google Scholar

• Single center study investigating the STEC carrier prevalence after azithromycin therapy after the STEC O104:H4 outbreak in Germany in 2011.

• Cover TL, Aber RC. Yersinia enterocolitica. N Engl J Med. 1989;321:16–24.
   PubMed Web of Science ®Google Scholar
• Aboutaleb N, Kuijper EK, Van Dissel JT. Emerging infectious colitis. Curr Opin Gastroenterol. 2014;30:106–115.
   PubMed Web of Science ®Google Scholar
• Hof H. An update on the medical management of listeriosis. Expert Opin Pharmacother. 2004;5:1727–1735.
   PubMed Web of Science ®Google Scholar
• Yde M, Naranjo M, Mattheus W, et al. Usefulness of the European Epidemic Intelligence Information System in the management of an outbreak of listeriosis, Belgium, 2011. Euro Surveill. 2012;17:20279.
   PubMedGoogle Scholar
• Harris JB, Larocque RC, Qadri F, et al. Cholera. Lancet. 2012;379:2466–2476.
   PubMed Web of Science ®Google Scholar
• Leibovici-Weissman Y, Neuberger A, Bitterman R, et al. Antimicrobial drugs for treating cholera. Cochrane Database Syst Rev. 2014;6:CD008625.
   PubMedGoogle Scholar
• Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372:825–834.
   PubMed Web of Science ®Google Scholar

• Comprehensive review of the massive burden of CDI in the United States

• Hensgens MP, Goorhuis A, Dekkers OM, et al. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother. 2011;67:742–748.
   PubMed Web of Science ®Google Scholar
• Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108:478–498.
   PubMed Web of Science ®Google Scholar

• Comprehensive review on all aspects of the guideline-based diagnosis and treatment of CDI focusing on the United States.

• Bauer MP, Kuijper EJ, Van Dissel JT, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect. 2009;15:1067–1079.
   PubMed Web of Science ®Google Scholar
• Debast SB, Bauer MP, Kuijper EJ, et al. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014;20(Suppl. 2):1–26.
   PubMed Web of Science ®Google Scholar

•• Current ESCMID guideline on the treatment of CDI in Europe.

• Zar FA, Bakkanagari SR, Moorthi KM, et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45:302–307.
   PubMed Web of Science ®Google Scholar
• Weis S, John E, Lippmann N, et al. [Clostridium difficile infection (CDI) in the course of time - an issue only for the internist?]. Zentralbl Chir. 2014;139:460–468.
   PubMed Web of Science ®Google Scholar
• Pillai A, Nelson R. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev. 2008;1:CD004611.
   PubMed Web of Science ®Google Scholar

• Cochrane analysis on the treatment of Clostridium difficile infections with probiotics.

• Johnston BC, Ma SS, Goldenberg JZ, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Ann Intern Med. 2013;157:878–888.
   Web of Science ®Google Scholar
• Allen SJ, Wareham K, Wang D, et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2013;382:1249–1257.
   PubMed Web of Science ®Google Scholar

•• Randomised, double-blind, placebo-controlled multi-center study describing the treatment of AAD and CDI with probiotics; the authors state clearly that there is no evidence that a multistrain preparation of lactobacilli and bifidobacteria was effective in the prevention of AAD or CDI.

• Wagner M, Lavoie L, Goetghebeur M. Clinical and economic consequences of vancomycin and fidaxomicin for the treatment of Clostridium difficile infection in Canada. Can J Inf Dis Med Microbiol. 2014;25:87–94.
   PubMed Web of Science ®Google Scholar
• Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364:422–431.
   PubMed Web of Science ®Google Scholar
• Van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407–415.
   PubMed Web of Science ®Google Scholar

•• This paper describes the only available randomised-controlled study yet describing that FMT is significantly more effective for the treatment of recurrent CDI than the use of vancomycin.

• Petrof EO, Khoruts A. From stool transplants to next generation microbiota therapeutics. Gastroenterology. 2014;146:1573–1582.
   PubMed Web of Science ®Google Scholar
• Youngster I, Russell GH, Pindar C, et al. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA. 2014;312: 1772–1778.
   PubMed Web of Science ®Google Scholar

• This paper describes an open-label, single-group, pioneer study investigating the success rates of resolution of diarrhea following administration of FMT using frozen encapsulated inoculum from unrelated donors for recurrent CDI.

• Mattila E, Arkkila P, Mattila PS, et al. Rifaximin in the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2013;37:122–128.
   PubMed Web of Science ®Google Scholar
• Herpers BL, Vlaminckx B, Burkhardt O, et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis. 2009;48:1732–1735.
   PubMed Web of Science ®Google Scholar
• Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010;362:197–205.
   PubMed Web of Science ®Google Scholar
• Sandhu DK, Surawicz C. Update on chronic diarrhea: a run-through for the clinician. Curr Gastroenterol Rep. 2012;14:421–427.
   PubMedGoogle Scholar
• Lübbert C, Weis S. [Drug therapy of infectious diarrhea. Part 2: chronic diarrhea]. Internist. 2013;54:1513–1519.
   PubMed Web of Science ®Google Scholar
• Chen XM, Keithly JS, Paya CV, et al. Cryptosporidiosis. N Engl J Med. 2002;346:1723–1731.
   PubMed Web of Science ®Google Scholar
• Abubakar I, Aliyu SH, Arumugam C, et al. Prevention and treatment of cryptosporidiosis in immunocompromised patients. Cochrane Database Syst Rev. 2007;1:CD004932.
   PubMed Web of Science ®Google Scholar
• MacArthur RD, Dupont HL. Etiology and pharmacologic management of noninfectious diarrhea in HIV-infected individuals in the highly active antiretroviral therapy era. Clin Infect Dis. 2012;55:860–867.
   PubMed Web of Science ®Google Scholar
• Feasey NA, Healey P, Gordon MA. Review article: the aetiology, investigation and management of diarrhoea in the HIV-positive patient. Aliment Pharmacol Ther. 2011;34:587–603.
   PubMed Web of Science ®Google Scholar
• Tejman-Yarden N, Eckmann L. New approaches to the treatment of giardiasis. Curr Opin Infect Dis. 2011;24:451–456.
   PubMed Web of Science ®Google Scholar
• Wright SG. Protozoan infections of the gastrointestinal tract. Infect Dis Clin North Am. 2012;26:323–339.
   PubMed Web of Science ®Google Scholar
• Lalle M. Giardiasis in the post genomic era: treatment, drug resistance and novel therapeutic perspectives. Infect Disord Drug Targets. 2010;10:283–294.
   PubMedGoogle Scholar
• Granados CE, Reveiz L, Uribe LG, et al. Drugs for treating giardiasis. Cochrane Database Syst Rev. 2012;12:CD007787.
   PubMedGoogle Scholar

• Current Cochrane analysis on the antimicrobial treatment of giardiasis.

• Solaymani-Mohammadi S, Genkinger JM, Loffredo CA, et al. A meta-analysis of the effectiveness of albendazole compared with metronidazole as treatments for infections with Giardia duodenalis. PLoS Negl Trop Dis. 2010;4:e682.
   PubMed Web of Science ®Google Scholar
• Ross AP, Olds GR, Cripps AW, et al. Enteropathogens and chronic illness in returning travelers. N Engl J Med. 2013;368:1817–1825.
   PubMed Web of Science ®Google Scholar

• Comprehensive review on all aspects of travel-associated illnesses causing chronic diarrhoea

• Stanley SL Jr. Amoebiasis. Lancet. 2003;361:1025–1034.
   PubMed Web of Science ®Google Scholar
• Haque R, Huston CD, Hughes M, et al. Amebiasis. N Engl J Med. 2003;348:1565–1573.
   PubMed Web of Science ®Google Scholar
• Hodges K, Gill R. Infectious diarrhea: cellular and molecular mechanisms. Gut Microbes. 2011;1:4–21.
   Google Scholar
• Ralston KS, Petri WA Jr. Tissue destruction and invasion by Entamoeba histolytica. Trends Parasitol. 2011;27:254–263.
   PubMed Web of Science ®Google Scholar
• Adachi JA, Ericsson CD, Jiang ZD, et al. Azithromycin found to be comparable to levofloxacin for the treatment of US travelers with acute diarrhea acquired in Mexico. Clin Infect Dis. 2003;37:1165–1171.
   PubMed Web of Science ®Google Scholar
• Kantele A, Lääveri T, Mero S, et al. Antimicrobials increase travelers’ risk of colonization by extended-spectrum beta-lactamase producing Enterobacteriaceae. Clin Infect Dis. 2015;60:837–846.
   PubMed Web of Science ®Google Scholar

•• Recent cohort study from Finland showing that empirical antibiotic therapy for TD proved to be independent risk factors for contracting ESBL-producing Enterobacteriaceae.